DGAP-Adhoc
Carl Zeiss Meditec invests in innovative radiotherapy solution for wet age-related macular degeneration
Carl Zeiss Meditec AG / Key word(s): Alliance
22.12.2014 20:24
Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Anzeige
Carl Zeiss Meditec invests in innovative radiotherapy solution for wet age-
related macular degeneration
Jena, 22 December 2014: Carl Zeiss Meditec Inc., a 100%-owned subsidiary of
Carl Zeiss Meditec AG (ISIN: DE0005313704) has signed a collaboration
agreement with Oraya Therapeutics Inc., Newark, USA (Oraya). Over the past
few years, Oraya has developed the novel low energy radiation therapy
"Oraya
Therapy" for wet age-related macular degeneration (wet AMD) and introduced
it to the market.
Under the terms of the agreement, Carl Zeiss Meditec will provide funding
to
Oraya for the implementation of its growth strategy over a period of up to
two years and in turn receive rights for a participation in the company
reaching up to a majority stake after two years. The amount of the funding
provided to Oraya has not been disclosed. Carl Zeiss Meditec expects this
investment to further strengthen its role as global innovation leader in
ophthalmology as well as its existing portfolio of solutions for diagnosis
and therapy of eye diseases.
Contact for investors
Sebastian Frericks, Director Investor Relations, Carl Zeiss Meditec AG
Tel. +49 3641 220-116, E-Mail: investors.meditec@zeiss.com
Press contact
Jann Gerrit Ohlendorf, Director Corporate Communications, Carl Zeiss
Meditec AG
Tel. +49 3641 220-331, E-Mail: press.meditec@zeiss.com
22.12.2014 The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Carl Zeiss Meditec AG
Göschwitzer Str. 51-52
07745 Jena
Germany
Phone: +49 (0)3641 220-0
Fax: +49 (0)3641 220-112
E-mail: investors.meditec@zeiss.com,info.meditec@zeiss.com
Internet: www.meditec.zeiss.de
ISIN: DE0005313704
WKN: 531370
Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
in Berlin, Düsseldorf, Hamburg, Hannover, München, Stuttgart
End of Announcement DGAP News-Service
---------------------------------------------------------------------------
related macular degeneration
Jena, 22 December 2014: Carl Zeiss Meditec Inc., a 100%-owned subsidiary of
Carl Zeiss Meditec AG (ISIN: DE0005313704) has signed a collaboration
agreement with Oraya Therapeutics Inc., Newark, USA (Oraya). Over the past
few years, Oraya has developed the novel low energy radiation therapy
"Oraya
Therapy" for wet age-related macular degeneration (wet AMD) and introduced
it to the market.
Under the terms of the agreement, Carl Zeiss Meditec will provide funding
to
Oraya for the implementation of its growth strategy over a period of up to
two years and in turn receive rights for a participation in the company
reaching up to a majority stake after two years. The amount of the funding
provided to Oraya has not been disclosed. Carl Zeiss Meditec expects this
investment to further strengthen its role as global innovation leader in
ophthalmology as well as its existing portfolio of solutions for diagnosis
and therapy of eye diseases.
Contact for investors
Sebastian Frericks, Director Investor Relations, Carl Zeiss Meditec AG
Tel. +49 3641 220-116, E-Mail: investors.meditec@zeiss.com
Press contact
Jann Gerrit Ohlendorf, Director Corporate Communications, Carl Zeiss
Meditec AG
Tel. +49 3641 220-331, E-Mail: press.meditec@zeiss.com
22.12.2014 The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Carl Zeiss Meditec AG
Göschwitzer Str. 51-52
07745 Jena
Germany
Phone: +49 (0)3641 220-0
Fax: +49 (0)3641 220-112
E-mail: investors.meditec@zeiss.com,info.meditec@zeiss.com
Internet: www.meditec.zeiss.de
ISIN: DE0005313704
WKN: 531370
Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
in Berlin, Düsseldorf, Hamburg, Hannover, München, Stuttgart
End of Announcement DGAP News-Service
---------------------------------------------------------------------------
Diskutieren Sie über die enthaltenen Werte
Aktuelle Themen
Weitere Artikel des Autors
1 im Artikel enthaltener WertIm Artikel enthaltene Werte